Salvianolic Acid B

Salvianolic acid B (C₃₆H₃₀O₁₆, MW 718.61) is a polyphenolic ester formed from three danshensu units and one caffeic acid moiety that exerts cardioprotective, antioxidant, and anticancer effects by inhibiting COX enzymes, suppressing Akt/mTOR-driven autophagy, blocking TNF-α and NO signaling, and modulating TGF-β1/MAPK/Smad2/3 pathways. In preclinical murine colon cancer models, intraperitoneal administration at 10 mg/kg achieved a 43.4% tumor suppression rate, rising to 63.2% at 20 mg/kg, though oral bioavailability in rats is only 2.3% and no human clinical trial data currently exist.

Origin & History

Salvianolic acid B is a water-soluble polyphenolic compound isolated primarily from the dried roots of Salvia miltiorrhiza (Danshen), a perennial herb native to China and Japan cultivated extensively in the Sichuan, Shaanxi, and Hebei provinces of China. The roots are harvested after one to two growing seasons from plants thriving in well-drained, sandy loam soils at moderate altitudes, where the compound accumulates as a major hydrophilic constituent. It also occurs in smaller amounts in other Salvia species and related Lamiaceae family members, but commercial extraction is almost exclusively derived from Danshen root.

Historical & Cultural Context

Salvia miltiorrhiza (Danshen) has been documented in Chinese pharmacopoeias for over 2,000 years, appearing in classical texts such as the Shennong Bencao Jing (Divine Farmer's Classic of Materia Medica, circa 200 CE), where the dried root was classified as a superior-grade medicinal herb used to invigorate blood circulation, resolve blood stasis, and calm the mind (shen). Traditional Chinese medicine practitioners prescribed Danshen root decoctions and wine-processed preparations primarily for cardiovascular complaints, hepatic conditions, menstrual irregularities, and insomnia, with the hydrophilic fraction—now known to be dominated by salvianolic acid B—responsible for many of the observed aqueous-extract effects. The isolation and structural characterization of salvianolic acid B as a discrete polyphenolic entity occurred in the late 20th century, enabling mechanistic pharmacological research that validated several traditional use claims at the molecular level. Danshen-based injectable preparations containing salvianolic acids are still approved for clinical cardiovascular use in China, though these multi-component preparations cannot attribute effects solely to Sal B.

Health Benefits

- **Cardioprotection**: Salvianolic acid B scavenges reactive oxygen species and inhibits platelet aggregation and lipid peroxidation, protecting cardiomyocytes from ischemia-reperfusion injury in preclinical models through multi-pathway antioxidant activity.
- **Anticancer Activity**: By inducing autophagy via Akt/mTOR inhibition (upregulating LC3-II and Atg5) and blocking epithelial-mesenchymal transition through p-Snail/Slug modulation, Sal B suppressed tumor growth by 43.4–63.2% in murine MC38 colon cancer models at 10–20 mg/kg.
- **Hepatoprotection**: Sal B reduces hepatic fibrosis and oxidative liver damage in preclinical studies by downregulating TGF-β1 signaling, inhibiting stellate cell activation, and reducing collagen deposition in rodent models of liver injury.
- **Neuroprotection**: The compound attenuates neuroinflammation and oxidative stress in neuronal cells by scavenging free radicals and inhibiting ERK and NF-κB–driven inflammatory cascades, with preclinical evidence suggesting protection in models of Alzheimer's and Parkinson's disease.
- **Anti-inflammatory Effects**: Sal B inhibits cyclooxygenase (COX) enzymes, suppresses TNF-α expression, and reduces nitric oxide (NO) production, attenuating LPS-induced pulmonary microcirculatory disturbance at intravenous doses of 5 mg/kg/h in animal models.
- **Antiviral Potential**: Preliminary in vitro data indicate that Sal B interferes with viral replication mechanisms relevant to SARS-CoV-2 (COVID-19) and other pathogens, likely through inhibition of key proteases and modulation of host immune signaling, though no human trial data exist.
- **Anti-obesity Effects**: Sal B has demonstrated free radical scavenging and lipid-lowering properties in preclinical models, reducing adipogenesis markers through AMPK-related pathways, positioning it as a candidate for metabolic syndrome research.

How It Works

Salvianolic acid B exerts its antioxidant effects through direct scavenging of hydroxyl radicals, superoxide anions, and peroxynitrite, enabled by its catechol and carboxylate moieties, and by upregulating endogenous antioxidant enzymes including superoxide dismutase and catalase. In cancer biology, it inhibits the Akt/mTOR signaling axis, leading to autophagy induction evidenced by increased LC3-II and Atg5 protein expression, while simultaneously suppressing epithelial-mesenchymal transition by modulating E-cadherin, N-cadherin, vimentin, and the transcription factors p-Snail and Slug in breast cancer cells; in non-small cell lung cancer, it blocks TGF-β1-induced proliferation via MAPK and Smad2/3 pathway inactivation. Its anti-inflammatory actions are mediated through inhibition of COX-1 and COX-2 enzymes, suppression of ERK phosphorylation, and reduction of TNF-α and inducible nitric oxide synthase (iNOS) expression downstream of NF-κB activation. Cardioprotective effects additionally involve inhibition of platelet aggregation, reduction of intracellular calcium overload, and modulation of mitochondrial membrane potential, collectively attenuating ischemia-reperfusion injury in preclinical cardiac preparations.

Scientific Research

The evidence base for salvianolic acid B consists almost entirely of in vitro cell-culture experiments and in vivo rodent or canine pharmacokinetic and efficacy studies; no randomized controlled trials in human subjects have been published to date. Preclinical oncology studies in C57BL/6 mice inoculated with MC38 colon cancer cells demonstrated statistically significant tumor suppression rates of 43.4% at 10 mg/kg and 63.2% at 20 mg/kg, establishing dose-dependent antitumor activity. Pharmacokinetic characterization in conscious rats following oral gavage (500 mg/kg) yielded an absolute bioavailability of 2.3% (AUC 582 ± 222 min·μg/mL; Cmax 1.5 μg/mL; t½ 248 min), with similarly poor oral bioavailability of 1.07 ± 0.43% observed in dogs, highlighting a significant translational challenge for human supplementation. The overall evidence quality is low-to-moderate for preclinical endpoints and absent for human clinical outcomes, necessitating cautious interpretation of all reported bioactivities.

Clinical Summary

No peer-reviewed randomized controlled trials evaluating salvianolic acid B as an isolated compound in human participants have been identified in the current literature. The compound's parent plant extract (Danshen) has been studied in cardiovascular and hepatic contexts in traditional Chinese medicine clinical settings, but these trials do not isolate Sal B's specific contribution. Preclinical studies provide quantified efficacy signals—tumor suppression of 43.4–63.2% in murine models, attenuation of LPS-induced pulmonary microvascular disruption at 5 mg/kg/h IV—but the profound translational gap introduced by 2.3% oral bioavailability in rats means human dose-response relationships remain entirely undetermined. Confidence in clinical benefit for any indication must be rated as very low pending adequately powered human trials with pharmacokinetically validated dosing strategies.

Nutritional Profile

Salvianolic acid B is a pure phytochemical compound (not a whole food) and does not contribute macronutrients, vitamins, or minerals in supplemental quantities. Its molecular structure (C₃₆H₃₀O₁₆, MW 718.61) comprises a trimeric ester of danshensu (3,4-dihydroxyphenyllactic acid) and caffeic acid, conferring a high phenolic hydroxyl group density that underlies its potent antioxidant capacity (DPPH IC₅₀ values reported in low micromolar ranges in vitro). In crude Danshen root, Sal B typically constitutes the single most abundant water-soluble constituent, often representing 1–3% of dried root weight depending on cultivar and growing conditions, though purified extracts can be concentrated to 85–98% purity. Bioavailability is severely limited orally (2.3% in rats) due to poor intestinal absorption, extensive first-pass hepatic metabolism, and hepatobiliary excretion, with linear pharmacokinetics demonstrated across the 0.5–200 μg/mL concentration range.

Preparation & Dosage

- **Purified Powder (Research Grade)**: Available at ≥85% purity (LC/MS-ELSD) or ≥94% purity (HPLC); soluble in water at ≥5 mg/mL; used in preclinical studies at 10–20 mg/kg IP in mice and 100 mg/kg IV or 500 mg/kg oral in rats—no established human equivalent dose exists.
- **Danshen Root Extract (Traditional/Supplement Form)**: Standardized hydrophilic Danshen extracts containing Sal B as a major constituent are available; standardization typically targets total salvianolic acids at 5–10% by HPLC, but Sal B-specific content varies widely.
- **Intravenous Administration (Preclinical Only)**: IV dosing in rats at 100 mg/kg produced Cmax ~910 μg/mL and AUC 5030 ± 565 min·μg/mL, providing substantially higher systemic exposure than oral routes; IV formulations are investigational only.
- **Oral Bioavailability Consideration**: Due to 2.3% oral bioavailability in rats (1.07% in dogs), effective oral human doses—if ever established—would likely require novel delivery systems (nanoparticles, phospholipid complexes) to achieve therapeutic plasma concentrations.
- **Extraction Methods for Standardized Preparations**: 30% ethanol reflux extraction yields 57.7% Sal B content; alcohol-aqueous extraction with chitosan and macroporous resin achieves 85.50%; counter-current chromatography from 500 mg crude extract yields 342 mg at 98% purity.
- **Timing**: Preclinical pharmacokinetic data show Cmax at 0.5–1 hour post-oral dosing, with detectability up to 180 minutes; plasma protein binding is 83.78 ± 10.5%, suggesting potential for distribution limitations in vivo.

Synergy & Pairings

Salvianolic acid B is frequently studied alongside the lipophilic tanshinone fraction of Danshen (particularly tanshinone IIA), and the two compound classes are thought to exert complementary cardioprotective effects—salvianolic acids addressing oxidative stress and platelet function through aqueous-phase mechanisms while tanshinones modulate lipid-phase membrane integrity and mitochondrial function. Preclinical research suggests co-administration with puerarin (from Pueraria lobata) may enhance coronary vasodilation and reduce myocardial ischemic injury beyond either compound alone, consistent with traditional TCM formulas pairing Danshen with kudzu root. Vitamin C and other polyphenolic antioxidants such as quercetin may theoretically regenerate the oxidized catechol groups of Sal B, sustaining its radical-scavenging capacity, though this synergy has not been formally quantified in controlled studies.

Safety & Interactions

Comprehensive human safety data for isolated salvianolic acid B do not exist, as no clinical trials have been conducted; preclinical rodent studies have administered up to 500 mg/kg orally without reported acute toxicity signals, but these findings cannot be directly extrapolated to human safety thresholds. Because Sal B inhibits platelet aggregation and modulates coagulation-related pathways, theoretical interactions with anticoagulant and antiplatelet drugs (warfarin, aspirin, clopidogrel) are plausible and would require monitoring if human use were established. Its parent plant Danshen is documented to potentiate warfarin anticoagulation in clinical case reports, raising concern that concentrated Sal B preparations could carry similar risk, particularly in patients with bleeding disorders or those undergoing surgery. Pregnancy and lactation safety is entirely unstudied for the isolated compound; given the absence of safety data and the potent bioactivity profile, use during pregnancy or breastfeeding is not advisable, and individuals on cardiovascular or immunosuppressive medications should consult a physician before consuming concentrated Danshen-derived preparations.